SPRB
NASDAQSpruce Biosciences Inc.
Spruce Biosciences Inc. (SPRB) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for SPRB, including 3 press releases and news items. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $0
- Revenue growth
- -100.0%
- Net income, FY2025
- -$38.97M
- Cash
- $96.30M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks370%
2026-05-172026-11-08
Mix1490d
- Other11(79%)
- SEC Filings2(14%)
- Analyst1(7%)
Activity · 52 weeks10055 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRSpruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx BiosciencesTransaction Expected to Create Two Independent, Publicly Traded Companies with Distinct Strategic Priorities, Separate Capital Structures and Dedicated TeamsUp to $50 Million Committed to Adrenyx from Leading Healthcare-Dedicated InvestorAdrenyx to Advance CRHX-101 (Formerly SPR-202), an Investigational Monoclonal Antibody Designed to Address an Upstream Driver of Classic Congenital Adrenal Hyperplasia ("CAH")Distribution of Adrenyx Common Stock to Spruce Stockholders on a Pro Rata Basis Expected in First Half of 2027Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with signific
- PRSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026 at 11:30 a.m. ET in Boston, MA.Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days following the live presentation.About Spruce Biosciences Spruce Biosciences is a late-stage bi
- PRSpruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst ConferenceSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026. An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days following the live presentation. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neur
- PRSpruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual MeetingSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenuated Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 55th Child Neurology Society (CNS) Annual Meeting, taking place October 14–17, 2026, in Montréal, Québec, Canada. The poster will be available on the Spruce Biosciences website fol
- ANALYSTLake Street initiated coverage on Spruce Biosciences with a new price targetLake Street initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $149.00
- PRSpruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days.About Spruce BiosciencesSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and comme
- PRSpruce Biosciences Announces Launch of MPS3BStudy.comWebsite Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory Study TA-ERT EAP and TrAnsform Confirmatory Study Both Expected to Initiate in the Fourth Quarter of 2026 Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn abo
- PRSpruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026FDA Found Spruce's Chemistry, Manufacturing and Controls (CMC) Comparability Strategies Reasonable to Support the BLA Following Technology Transfer to Leading Global Biologics Manufacturer Spruce and FDA Aligned on the Overall Content and Format of the Planned BLA, Including Structure of the Integrated Efficacy and Safety Summaries Spruce Continues to Advance Its Planned Biologics License Application (BLA) on the Accelerated Approval Pathway Based on Reduction of Cerebrospinal Fluid Heparan Sulfate Non-Reducing Ends (CSF HS-NRE) Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurol
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSEC Form 10-Q filed by Spruce Biosciences Inc.10-Q - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesBiologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fourth Quarter of 2026 Strengthened Leadership Team with the Appointments of Adrian Quartel, M.D., FFPM, as Chief Medical Officer and Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter
- PRCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesInvestment Broadens Patient Access to Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B in the TA-ERT Expanded Access Program (EAP) TA-ERT EAP Expected to Initiate in the Fourth Quarter of 2026 Spruce Biosciences, Inc. (NASDAQ:SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spruce. The proceeds will be used to partially fund TA-ERT EAP, helping to broaden patient access to investigational TA-
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spruce Biosciences Inc.SCHEDULE 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- PRSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical DevelopmentDr. Cohen Pfeffer Brings More Than a Decade of Clinical Development Leadership, Including Deep Experience with Enzyme Replacement Therapies for Rare Pediatric Neurodegenerative DisordersSpruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective today. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning clinical development, product portfolio development and medica
- INSIDERSEC Form 4 filed by Chief Medical Officer Quartel Adrian W4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quartel Adrian W3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
- SECSpruce Biosciences Inc. filed SEC Form 8-K: Leadership Update8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
- PRSpruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical OfficerAccomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic DisordersSpruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior roles spanning c
- ANALYSTB. Riley Securities initiated coverage on Spruce Biosciences with a new price targetB. Riley Securities initiated coverage of Spruce Biosciences with a rating of Buy and set a new price target of $160.00
- INSIDERCHIEF EXECUTIVE OFFICER Szwarcberg Javier B. was granted 266 shares, increasing direct ownership by 1% to 19,270 units (SEC Form 4)4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
- PRSpruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare SummitSpruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.The B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit will take place on July 16, 2026, at the InterContinental Boston hotel in Boston, MA.Participation in the summit is by invitation only. Investors interested in scheduling an in-person
- PRSpruce Biosciences Joins the Russell 3000® IndexInclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. The Russell 3000® Index measures the
SPRB FAQ
11 questionsWhat does Spruce Biosciences Inc. do?
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH...What is the latest news on SPRB?
In the last 30 days Quantisnow tracked 3 wire items for SPRB: 3 press releases and news items. The most recent was published on November 9, 2026.What is SPRB revenue?
Spruce Biosciences Inc. (SPRB) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is SPRB profitable?
No. Spruce Biosciences Inc. reported a net loss of $38.97M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SPRB have?
Spruce Biosciences Inc. reported $96.30M in cash and cash equivalents and $7.09M of debt on its most recent balance sheet in SEC filings.Where does SPRB stock trade?
Spruce Biosciences Inc. (SPRB) is listed on NASDAQ.What sector and industry is SPRB in?
Spruce Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spruce Biosciences Inc. go public?
Spruce Biosciences Inc. (SPRB) completed its IPO in 2020.What are analysts saying about SPRB?
Across the last 8 analyst actions on Spruce Biosciences Inc., there were 2 upgrades and 1 downgrade. The most recent action was from Lake Street: Buy with a $149.00 price target on 2026-09-17. Recent price targets range from $123.00 to $283.00.What companies are similar to SPRB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRB side-by-side with any of them on Quantisnow.How can I track SPRB on Quantisnow?
Quantisnow aggregates Spruce Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRB to receive live email and push alerts on every new disclosure.